EGFR and breast carcinoma: To confirm these data in a larger dataset with clinical annotation, we evaluated the incidence of EGFR amplification (≥4.5 CN) in patients with breast cancer profiled by Caris Life Sciences (Caris), where the majority of patients profiled had metastatic breast cancer (Table 1).